EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2‐Month Ready‐to‐Use Long‐Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder

Yanlin Wang, Matthew Harlin, Frank Larsen, Xiaofeng Wang, Wansu Park, Benjamin Rich, Jogarao V Gobburu, Arash Raoufinia

Clinical Pharmacology in Drug Development · 2024-06 · 13 (6) · 631-643

DOI: 10.1002/cpdd.1397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 11.04.2024. Verfasst von Yanlin Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA. Hauptthemen laut MEDLINE: Aripiprazole, Schizophrenia, Bipolar Disorder, Antipsychotic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A ready‐to‐use (RTU) long‐acting injectable (LAI) formulation of aripiprazole monohydrate for administration once every 2 months, available in 960 mg (Ari 2MRTU 960) or 720 mg doses, has been developed for the treatment of schizophrenia or bipolar I disorder. A previously developed and validated population pharmacokinetic model for characterizing aripiprazole plasma concentrations following administration of oral aripiprazole or aripiprazole once‐monthly (AOM) intramuscular injection was expanded to include the RTU LAI formulation of aripiprazole (Ari RTU LAI). Overall, 8899 aripiprazole pharmacokinetic samples from 1191 adults from 10 clinical trials were included in the final combined analysis data set. Aripiprazole plasma concentration‐time profiles were simulated for various Ari RTU LAI initiation and maintenance scenarios in 1000 virtual patients. Diagnostic plots demonstrated that the final population pharmacokinetic model, which incorporated data for oral aripiprazole, AOM, and Ari RTU LAI, adequately described aripiprazole concentrations following Ari RTU LAI administration. Absorption of Ari RTU LAI was modeled by a parallel zero‐order and lagged first‐order process. Simulations across multiple scenarios were performed to inform dosing recommendations, including various treatment initiation regimens for a 2‐monthly formulation of Ari RTU LAI in patients with or without prior stabilization on oral aripiprazole, and for patients switching from AOM. Additional simulations accounted for missed/delayed doses, cytochrome (CYP) 2D6 metabolizer status, and concomitant use of CYP2D6 or CYP3A4 inhibitors. Overall, simulations across a variety of scenarios demonstrated an Ari RTU LAI pharmacokinetic exposure profile that was comparable to AOM, with a longer dosing interval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AripiprazoleSchizophreniaBipolar DisorderAntipsychotic AgentsDelayed-Action PreparationsModels, BiologicalComputer SimulationHumansAdultInjections, IntramuscularMaleFemaleMiddle AgedYoung AdultAdolescentAgedDrug Administration Schedule

Stichwörter der Autor:innen

2‐month ready‐to‐usearipiprazolelong‐acting injectablepopulation pharmacokineticssimulations

Substanzen

AripiprazoleAntipsychotic AgentsDelayed-Action Preparations

Autor:innen und Institutionen

  • Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
  • H. Lundbeck A/S, Valby, Denmark.
  • Alnylam Pharmaceuticals, Cambridge, MA, USA.
  • InnoMx Inc., Outremont, QC, Canada.
  • School of Pharmacy, University of Maryland, Baltimore, MD, USA.

Zitieren

APA

Wang, Y., Harlin, M., Larsen, F., Wang, X., Park, W., Rich, B., Gobburu, J. V., & Raoufinia, A. (2024). Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2‐Month Ready‐to‐Use Long‐Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder. Clinical Pharmacology in Drug Development, 13(6), 631-643. https://doi.org/10.1002/cpdd.1397

Vancouver

Wang Y, Harlin M, Larsen F, Wang X, Park W, Rich B, et al. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2‐Month Ready‐to‐Use Long‐Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder. Clinical Pharmacology in Drug Development. 2024;13(6):631-643. doi:10.1002/cpdd.1397

BibTeX
@article{Wang2024,
  author = {Wang, Yanlin and Harlin, Matthew and Larsen, Frank and Wang, Xiaofeng and Park, Wansu and Rich, Benjamin and Gobburu, Jogarao V and Raoufinia, Arash},
  title = {Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2‐Month Ready‐to‐Use Long‐Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  volume = {13},
  number = {6},
  pages = {631--643},
  doi = {10.1002/cpdd.1397}
}
Kostenlos starten →